In order to test the metabolic consequences of glutaminase inhibition, we carried out intracellular metabolite analysis in response to CB-839 treatment in two NF1 associated (MPNST and ST8814) and two wild-type NF1 cell lines (LS141 and STS26T). This evidence concerns the gene GLS and malignant peripheral nerve sheath tumor.